Primary CNS lymphoma commonly expresses immune response biomarkers | Zendy

Alexander Ou | Zendy; Ashley Sumrall | Zendy; Surasak Phuphanich | Zendy; David Spetzler | Zendy; Zoran Gatalica | Zendy; Joanne Xiu | Zendy; Sharon K. Michelhaugh | Zendy; Andrew Brenner | Zendy; Manjari Pandey | Zendy; Santosh Kesari | Zendy; W. Michael Korn | Zendy; Sandeep Mittal | Zendy; Jason R. Westin | Zendy; Amy B. Heimberger | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Primary CNS lymphoma commonly expresses immune response biomarkers

Author(s) -

Alexander Ou,

Ashley Sumrall,

Surasak Phuphanich,

David Spetzler,

Zoran Gatalica,

Joanne Xiu,

Sharon K. Michelhaugh,

Andrew Brenner,

Manjari Pandey,

Santosh Kesari,

W. Michael Korn,

Sandeep Mittal,

Jason R. Westin,

Amy B. Heimberger

Publication year - 2020

Publication title -

neuro-oncology advances

Language(s) - Uncategorized

Resource type - Journals

ISSN - 2632-2498

DOI - 10.1093/noajnl/vdaa018

Subject(s) - biology , missense mutation , microsatellite instability , cancer research , lymphoma , immune system , immune checkpoint , nonsynonymous substitution , mutation , gene , immunohistochemistry , primary central nervous system lymphoma , microbiology and biotechnology , immunotherapy , genetics , immunology , microsatellite , allele , genome

Based on TMB biomarker expression, over 90% of PCNSL patients may benefit from the use of immune checkpoint inhibitors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research